News | February 18, 2022
Bayer raises peak sales for Nubeqa to exceed €3 billion
Darolutamide is developed jointly by Bayer and Orion Corporation
Darolutamide is developed jointly by Bayer and Orion Corporation
Ligand expects 2022 royalties of $55 million to $60 million, material sales of $40 million to $50 million, and contract revenue of $52 million to $62 million.
Application based on the pivotal Phase 3 TRANSFORM study in which Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years
Resolv ER may remedy leading causes of blindness in adults
Funding will support continued advancement of Centauri’s antimicrobial resistance research to identify novel therapeutic candidates using its proprietary Alphamer platform
Nirsevimab is the first investigational long-acting antibody designed to protect all infants for the respiratory syncytial virus season with a single dose
The funds will be used to expand digital product offerings, grow their online customer base, and launch their flagship clinic in Bengaluru
New subsidiaries to be established in Malaysia, Taiwan, Singapore, and Hong Kong
These results will be presented on 17 February at the 2022 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium
The recommendation has been sent to the DCGI for approval
Subscribe To Our Newsletter & Stay Updated
